key: cord-1054479-fcng6yov authors: Chadeau-Hyam, M.; Tang, D.; Eales, O.; Bodinier, B.; Wang, H.; Jonnerby, J.; Whitaker, M.; Elliott, J.; Haw, D.; Walters, C. E.; Atchinson, C.; Diggle, P. J.; Page, A. J.; Ashby, D.; Barclay, W.; Taylor, G.; Cooke, G.; Ward, H.; Darzi, A.; Donnelly, C. A.; Elliott, P. title: The Omicron SARS-CoV-2 epidemic in England during February 2022 date: 2022-03-13 journal: nan DOI: 10.1101/2022.03.10.22272177 sha: 4103f316c5cbe4acb12d9208936ccdcfec3eab78 doc_id: 1054479 cord_uid: fcng6yov Background: The third wave of COVID-19 in England peaked in January 2022 resulting from the rapid transmission of the Omicron variant. However, rates of hospitalisations and deaths were substantially lower than in the first and second waves Methods: In the REal-time Assessment of Community Transmission-1 (REACT-1) study we obtained data from a random sample of 94,950 participants with valid throat and nose swab results by RT-PCR during round 18 (8 February to 1 March 2022). Findings: We estimated a weighted mean SARS-CoV-2 prevalence of 2.88% (95% credible interval [CrI] 2.76-3.00), with a within-round reproduction number (R) overall of 0.94 (0.91-0.96). While within-round weighted prevalence fell among children (aged 5 to 17 years) and adults aged 18 to 54 years, we observed a level or increasing weighted prevalence among those aged 55 years and older with an R of 1.04 (1.00-1.09). Among 1,195 positive samples with sublineages determined, only one (0.1% [0.0-0.5]) corresponded to AY.39 Delta sublineage and the remainder were Omicron: N=390, 32.7% (30.0-35.4) were BA.1; N=473, 39.6% (36.8-42.5) were BA.1.1; and N=331, 27.7% (25.2-30.4) were BA.2. We estimated an R additive advantage for BA.2 (vs BA.1 or BA.1.1) of 0.40 (0.36-0.43). The highest proportion of BA.2 among positives was found in London. Interpretation: In February 2022, infection prevalence in England remained high with level or increasing rates of infection in older people and an uptick in hospitalisations. Ongoing surveillance of both survey and hospitalisations data is required. Funding: Department of Health and Social Care, England. Evidence before this study A search of PubMed using title or abstract terms ("Omicron" or "BA.1" or "BA.2") and "prevalence" without language or other restrictions, identified 51 results (with no duplicates). All 51 results were evaluated, with 18 deemed relevant. One study focused on We analysed data from throat and nose swabs collected at home by a randomly selected sample of residents of England, aged 5 years and older, obtained during round 18 (8 February to 1 March 2022) of the REal-time Assessment of Community Transmission-1 (REACT-1) study. We estimated a weighted prevalence of SARS-CoV-2 of 2.88% (95% CrI 2.76-3.00) in England in February 2022, which was substantially lower than that estimated in January 2022 (4.41% [4.25-4.56] ). The within-round dynamics differed by age group with weighted prevalence falling among children (aged 5 to 17 years) with an R of 0.79 (0.74-0.84) and adults aged 18 to 54 years with an R of 0.92 (0.89-0.96), in contrast to the level or increasing weighted prevalence among those aged 55 years and older with an R of 1.04 (1.00-1.09). Exponential models estimated a daily growth rate advantage of 0.12 (0.11-0.13) in the odds of BA.2 (vs BA.1 or BA.1.1) corresponding to an R additive advantage of 0.40 (0.36-0.43). Random community surveys of SARS-CoV-2 provide robust insights into transmission dynamics and identify groups at heightened risk of infection based on estimates of Introduction As part of the government's plan for "living with COVID-19" 1 , domestic legal restrictions concerning SARS-CoV-2 infection ended in England on 24 February 2022 2 , fourteen months after the UK began its national SARS-CoV-2 vaccination programme 3 . The removal of legal restrictions came just over a month after the third-wave peak in deaths within 28 days of a positive SARS-CoV-2 test in England, and the rapid rise in transmission related to the Omicron variant. 4 These occurred despite high levels of vaccine coverage in adults and children aged 12 years and older 5 but with substantially lower peak rates of hospitalisations and deaths than in the first and second waves in April 2020 and January 2021, respectively 6 . Changes in population-wide testing availability and policies have complicated interpretation of the routine SARS-CoV-2 testing data. These include the fact that those testing positive using a lateral flow device (LFD) are no longer required to take confirmatory PCR tests 7 , variable test-seeking behaviour and periods when the demand for testing (LFD and PCR) exceeded supply. Reported cases now include those that were LFD-positive only, PCR-positive only and positive on both types of test, although it is unclear what proportion of people who undertake a home-test LFD report the results, and most asymptomatic infections go unreported. In addition, from 31 January 2022, the national reporting includes reinfections for the first time 8 . Against this backdrop, random community surveys of SARS-CoV-2 provide situational awareness based on unbiased estimates of population prevalence 9 . The REal-time Assessment of Community Transmission-1 (REACT-1) study has obtained throat and nose swabs from random samples of the population of England (5 years of age and older) approximately monthly since May 2020, giving estimates of the community prevalence of swab-positivity in England and insights into the underlying transmission dynamics. Here we report the results from the eighteenth round of data collection of the REACT-1 study, in which samples were collected from 8 February to 1 March 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The REACT-1 study has conducted cross-sectional surveys of random samples of the population of England at ages 5 years and older 10 over two-to three-week periods on a monthly basis since May 2020 (exceptions were December 2020 and August 2021). Participants have provided a self-administered throat and nose swab which was then analysed for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR As previously described 14, 15 , to the beginning of May 2021, we obtained random samples with approximately equal numbers of people in each lower-tier local authority area (LTLA) in England, but from round 12 (20 May to 7 June 2021), to improve sample representativeness, we changed our sampling procedure to be in proportion to population size at LTLA level. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; test, those aged 13 to 17 and 35 to 44 were offered a gift voucher worth £10 while those aged 18 to 34 were offered a gift voucher worth £20. We used random iterative method (rim) weighting 16 to provide prevalence estimates for the population of England as a whole, adjusting for age, sex, deciles of the Index of Multiple Deprivation, LTLA counts, and ethnic group. Samples testing positive with Ct values of 34 or less in the N gene and/or the E gene were sent for viral genome sequencing to the Quadram Institute, Norwich, UK. We used the ARTIC protocol 17 (version 4.1) for viral RNA amplification, CoronaHiT for preparation of sequencing libraries, 18 the ARTIC bioinformatics pipeline 17 and assigned sublineages using PangoLEARN (version 2022-02-02). 19 Sequencing data for the present analyses were available for positive swabs obtained up to 21 February 2022. For each round, we estimated weighted prevalence and 95% credible intervals overall and by socio-demographic and other variables. We used logistic regression to estimate the odds of testing positive by employment, ethnicity, household size, children in household, urban status, and deprivation, adjusting for age, region and the other variables examined. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint fever, new persistent cough) vs those not declaring any symptom in the month prior to swabbing. To visualise temporal trends in SARS-CoV-2 swab positivity, we applied a Bayesian penalised-spline (P-spline) model 21 to daily weighted prevalence data. Specifically, we used a No-U-Turn Sampler in logit space and data were split into approximately 5-day sections by regularly spaced knots. Edge effects were minimised by adding further knots beyond the study period. We used fourth-order basis splines (b-splines) over the knots including a second-order random-walk prior distribution on the coefficients of the b-splines to guard against overfitting; the use of this prior distribution penalised changes in the growth rate unless supported by the data. 15, 22 We also fit P-splines separately to three broad age groups 23 We estimated the reproduction number R from the daily growth rate from where is the exponential growth (or decay) rate, and the shape parameter and the rate parameter were set to 0.89 and 0.27, respectively ensuring under a gamma distribution assumption, a mean generation time of 3.3 days and a standard deviation of 3.5 days, as previously reported. 20 We estimated a neighbourhood smoothed prevalence at the LTLA level by randomly is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We used R software 24 for the data analyses. We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of this manuscript. A total of 635,000 individuals were invited to participate in round 18 (Table S1 ). This was the second highest weighted prevalence observed throughout the REACT-1 study after that in round 17 ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint We determined a total of 1,195 sublineages (85.6%; 95% CI 83.9-87.6) from the 1,392 positive samples obtained to 21 February 2022 with sequencing data (Table 1) . Of these one (0.1%; 95% CI 0.0-0.5) corresponded to AY.39 Delta sublineage and was detected in a participant living in East of England who did not report having travelled within or outside the UK in the two weeks prior to swabbing. All other sublineages were Omicron variant and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Table S2) . Weighted prevalence in round 18 by age ranged from 1.68% (1.41-2.01) in those aged 75 years and older to 4.69% (4.01-5.48) in those aged 5 to 11 years. Weighted prevalence in round 18 was higher in the youngest age group compared to all other ages (Table S3A, Figure 3B ). At all ages, weighted prevalence in round 18 was lower than that observed in round 17 Figure 3E ). We found higher weighted prevalence in (i) larger households compared to single-person households, (ii) households with one or more children compared to households without 11 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint children, (iii) those having been in contact with a (confirmed or suspected) COVID-19 case compared to those without such contact, (iv) those not shielding, and (v) those reporting 'classic' COVID-19 or any symptoms in the month prior to swabbing compared to those not reporting any symptoms (Table S3B ). In multivariable logistic regression we found elevated risk of swab positivity in healthcare or care home workers (vs other non-essential workers) with mutually adjusted OR of 1.18 (1.02-1.36), and in participants living in households with one or more children (vs household without children) with mutually adjusted OR of 1.35 (1.19-1.53) (Table S4 ). Notably, following a decline in hospitalisations in England from a peak around 9 January 2022, hospitalisations have begun to rise again from around 26 February, toward the end of round 18 25 . It will be important to continue to monitor infections, and hospitalisations, among older people, many of whom will have received a booster dose of vaccine 4 to 5 months earlier, with evidence suggesting waning of immunity a few weeks post booster dose 26 . In this regard, the UK government has announced a fourth dose of vaccine will be offered to vulnerable people, including those over the age of 75 years, from spring 2022 27 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The third wave of infections in England due to Omicron was initially driven by BA.1, but by 10 January 2022, 53 sequences of the Omicron sublineage BA.2 had been identified in the UK 29 . BA.2 is widespread globally and has been phylogenetically divided into five groups 30 UKHSA has reported, with moderate confidence, that the transmissibility of BA.2 rather than its immune evasion were driving its growth rate advantage. This is supported by subsequent antigenic characterisation indicating that the BA.1 and BA.2 sublineages are antigenically equidistant from wildtype SARS-CoV-2 32 . In our own data, the lower Ct values (higher viral load) for BA.2 compared with BA.1 and BA.1.1 could indicate that BA.2 infections are more recent and/or that the higher viral loads are leading to greater transmissibility 33, 34 . Furthermore, UKHSA reported, with moderate confidence, that the severity of BA.2 was similar to that of BA.1 31 , which is associated with lower rates of hospitalisation and deaths during the Omicron wave relative to those during the first wave (wildtype) and second wave (Alpha) in England 14 . Our data indicate a geographical divide in BA.2 Omicron infections, with more infections due to BA.2 in the south compared to the north of the country. We found the highest proportion is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; the ground" of high levels of absenteeism for COVID-19 among healthcare staff during the peak of the Omicron epidemic 35 . Our study has limitations. We have observed a slow decline in response rates since the beginning of the study, from approximately 30% returning swabs with valid RT-PCR test results in round 1 (1 May to 1 June 2020) to 12.2% in round 17 (5 to 20 January 2022). To improve response rates and make the study more representative we included a small monetary incentive in round 18 among those aged 13 to 44 years, following a successful pilot. This had the result of more than doubling response rates at these ages, giving an overall response rate of 15.0%. We used rim weighting to correct the sample to the characteristics of the base population 16 . Unlike in previous rounds, the rim weighting correction led to only small changes in round 18 between the unweighted and weighted prevalence, reflecting the improved representativeness of the obtained sample. In conclusion, we report continued high prevalence of SARS-CoV-2 infections during is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figures Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; 1 and BA2 ) separately, distributions of Ct values are plotted for those reporting at least one symptom in the month prior to swabbing (orange), in those reporting any of the classic symptoms -loss or change of sense of smell or taste, fever, new persistent cough (red) -and those not reporting any symptoms (blue). Comparison of the distribution of Ct values in those reporting symptoms (any or at least one of the classic four COVID-19 symptoms) and those not reporting any symptoms was done using a Kruskal-Wallis test, and we report the corresponding p-value. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; Figure 3A . Comparison of an exponential model fit to round 18 (blue), an exponential model fit to round 17 and round 18 (red) and a P-spline model fit to all rounds of REACT-1 (black, shown here only for rounds 16, 17 and 18) . Shaded red region shows the 95% posterior credible interval for the exponential models, and the shaded grey region shows 50% (dark grey) and 95% (light grey) posterior credible interval for the P-spline model. Results are presented for each day (X axis) of sampling for round 16, round 17 and round 18 and the weighted prevalence of swab-positivity is shown (Y axis) on a log scale. Weighted observations (black dots) and 95% confidence intervals (vertical lines) are also shown. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint Figure 3B . Weighted prevalence of swab-positivity by age group for round 17 and round 18. Bars show the prevalence point estimates (grey for round 17 and orange for round 18) , and the vertical lines represent the 95% confidence intervals. Figure 3C . Comparison of P-spline models fit to SARS-CoV-2 swab-positivity data from all rounds of REACT-1 for those aged 17 years and under (red), those aged 18 to 54 years inclusive (blue) and those aged 55 years and over (green). Shaded regions show 50% (dark shade) and 95% (light shade) posterior credible interval for the P-spline models. Results are presented for each day (X axis) of sampling for round 16, round 17, and round 18 and the prevalence of swab-positivity is shown (Y axis) on a log scale. Weighted observations (dots) and 95% confidence intervals (vertical lines) are also shown. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint Figure 3D Weighted prevalence of swab-positivity by region for round 17 and round 18. Bars show the prevalence point estimates (grey for round 17 and orange for round 18) , and the vertical lines represent the 95% confidence intervals. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint Table S2 . Table of growth rates, reproduction numbers and doubling/halving times from exponential model fits on data from round 17 (5 to 20 January 2022) and round 18 (8 February to 1 March 2022) Table S3A . Weighted prevalence of SARS-CoV-2 swab-positivity in round 17 and round 18 by sex, age, region, urban status, employment type, and ethnic group. Table S3B . Weighted prevalence of SARS-CoV-2 swab-positivity in round 17 and round 18 by household size, number of children in the household, contact with a COVID-19 case, protective behaviours, symptom status and neighbourhood deprivation. Table S4 . Multivariable logistic regression for round 18. Results are presented as Odds Ratios (95% confidence interval) adjusted for age and sex and additionally for region and all other variables (mutually adjusted OR). . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 13, 2022. ; https://doi.org/10.1101/2022.03.10.22272177 doi: medRxiv preprint COVID-19 response: Living with COVID-19 Prime Minister sets out plan for living with COVID Coronavirus » week one: Implementing the covid vaccination programme Rapid increase in Omicron infections in England during December 2021: REACT-1 study UK summary People with a positive lateral flow test no longer required to take confirmatory PCR test COVID-19 daily dashboard amended to include reinfections Resurgence of SARS-CoV-2: Detection by community viral surveillance REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol Mapping income deprivation at a local authority level: 2019 -Office for National Statistics sifications/2011ruralurbanclassification Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant Weighting survey results ncov2019-artic-nf: A Nextflow pipeline for running the ARTIC network's fieldbioinformatics tools CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes Software package for assigning SARS-CoV-2 genome sequences to global lineages Estimation of the test to test distribution as a proxy for generation interval distribution for the Omicron variant in England. bioRxiv Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number The no-U-Turn Sampler: Adaptively setting path lengths in Hamiltonian Monte Carlo R: A language and environment for statistical computing COVID-19 Dashboard Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant A guide to the spring booster for those aged 75 years and older residents in care homes Fourth dose of COVID-19 vaccines in Israel SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 2 lineage spreads in clusters and is concentrated in Denmark Risk assessment for SARS-CoV-2 variant: VUI-22JAN-01 (BA.2) Antibody evasion properties of SARS-CoV-2 Omicron sublineages Viral loads observed under competing strain dynamics Estimating epidemiologic dynamics from cross-sectional viral load distributions Covid absences among NHS staff in England fall amid signs crisis is easing. The Guardian Table S1 . Unweighted and weighted prevalence of swab-positivity from REACT-1 across rounds 1 to 18.